Credit Suisse Group reaffirmed their outperform rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note released on Thursday morning, MarketBeat Ratings reports. Credit Suisse Group currently has a $147.00 price target on the biopharmaceutical company’s stock.

ALXN has been the subject of a number of other reports. TheStreet downgraded shares of Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, November 10th. BidaskClub raised shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, December 27th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price objective for the company in a report on Tuesday, October 31st. Raymond James Financial reaffirmed an outperform rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Finally, Royal Bank of Canada raised their price objective on shares of Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $153.10.

Alexion Pharmaceuticals (ALXN) traded up $0.70 during midday trading on Thursday, reaching $121.05. 1,747,222 shares of the company’s stock traded hands, compared to its average volume of 2,100,000. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The firm has a market cap of $27,040.00, a price-to-earnings ratio of 54.04, a price-to-earnings-growth ratio of 1.01 and a beta of 1.17. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS. sell-side analysts forecast that Alexion Pharmaceuticals will post 4.82 earnings per share for the current year.

In related news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.35% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Alexion Pharmaceuticals by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after purchasing an additional 318,375 shares during the last quarter. State Street Corp lifted its holdings in Alexion Pharmaceuticals by 5.0% during the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Alexion Pharmaceuticals by 3.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after purchasing an additional 215,005 shares during the last quarter. Jennison Associates LLC lifted its holdings in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Alexion Pharmaceuticals by 17.2% during the 2nd quarter. Northern Trust Corp now owns 2,966,636 shares of the biopharmaceutical company’s stock valued at $360,950,000 after purchasing an additional 435,482 shares during the last quarter. 94.27% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/01/21/alexion-pharmaceuticals-alxn-outperform-rating-reaffirmed-at-credit-suisse-group.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.